Doxorubicin

Generic Name: Doxorubicin

Brand Names: Adriamycin, Doxil, Myocet, Caelyx pegylated liposomal, Zolsketil pegylated liposomal, Myocet liposomal (previously Myocet), Celdoxome pegylated liposomal

Drug Type: Small Molecule

Chemical Formula: C_₂₇H_₂₉NO_₁₁

CAS Number: 23214-92-8

Unique Ingredient Identifier: 80168379AG

Background: Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius along side with daunorubicin, another cytotoxic agent, in 1970. Although they both have aglyconic and sugar moieties, doxorubicin's side chain terminates with a primary alcohol group compared to the methyl group of daunorubicin. Although its deta...

Indication: Doxorubicin is indicated for the treatment of neoplastic conditions like acute lymphoblastic leukemia, acute myeloblastic leukemia, Hodgkin and non-Hodgkin lymphoma, metastatic breast cancer, metastatic Wilms’ tumor, metastatic neuroblastoma, metastatic soft tissue and bone sarcomas, metastatic ovarian carcinoma, metastatic transitional cell bladder carcinom...

Associated Conditions: AIDS-related Kaposi's Sarcoma, Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Advanced Endometrial Cancer, Advanced Ovarian Cancer, Breast Cancer, Hodgkin's Lymphoma, Metastatic Bone Sarcomas, Metastatic Breast Cancer, Metastatic Soft Tissue Sarcoma, Metastatic Thyroid Cancer, Metastatic Urothelial Cancer, Multiple Myeloma (MM), Mycosis Fungoides (MF), Non-Hodgkin's Lymphoma (NHL), Sezary Syndrome, Waldenström's Macroglobulinemia (WM), Advanced Thymoma, Advanced uterine sarcoma, Metastatic Bronchogenic Carcinoma, Metastatic Gastric carcinoma, Metastatic Neuroblastoma, Metastatic Ovarian carcinoma, Metastatic Wilms' tumor

Associated Therapies: -

Clinical Trials

Blood Brain Barrier (BBB) Disruption Using Exablate Focused Ultrasound With Doxorubicin for Treatment of Pediatric DIPG

Phase 1

Recruiting

Conditions: Brain Tumor

Interventions: Device: Exablate
Drug: Doxorubicin

First Posted Date: 2022-11-29

Last Posted Date: 2023-11-03

Lead Sponsor: InSightec

Target Recruit Count: 10

Registration Number: NCT05630209

Locations: 🇺🇸
Nicklaus Children's Hospital, Miami, Florida, United States
🇺🇸
Children's National Medical Center, Washington, District of Columbia, United States

Blood Brain Barrier (BBB) Disruption Using Exablate Focused Ultrasound With Doxorubicin for Treatment of Pediatric DIPG

Phase 1

Recruiting

Conditions: Brain Tumor

Interventions: Device: Exablate
Drug: Doxorubicin

First Posted Date: 2022-11-14

Last Posted Date: 2023-11-03

Lead Sponsor: InSightec

Target Recruit Count: 3

Registration Number: NCT05615623

Locations: 🇨🇦
Sunnybrook Research Institute, Toronto, Ontario, Canada

Combination Therapy for Recurrent Ovarian Cancer

Phase 1

Recruiting

Conditions: Recurrent Ovarian Cancer

Interventions: Drug: DOXIL
Drug: Withaferin A
Drug: Ashwagandha
Drug: Combination of ASWD and DOXIL

First Posted Date: 2022-11-09

Last Posted Date: 2024-04-24

Lead Sponsor: Sham Sunder Kakar

Target Recruit Count: 72

Registration Number: NCT05610735

Locations: 🇺🇸
UofL Health Brown Cancer Center, Louisville, Kentucky, United States

Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma

Phase 3

Recruiting

Conditions: High-risk Large B-cell Lymphoma (LBCL)

Interventions: Biological: Axicabtagene Ciloleucel
Drug: Cyclophosphamide
Drug: Etoposide
Drug: Rituximab
Drug: Fludarabine
Drug: Doxorubicin
Drug: Vincristine
Drug: Prednisone

First Posted Date: 2022-11-04

Last Posted Date: 2024-12-06

Lead Sponsor: Kite, A Gilead Company

Target Recruit Count: 300

Registration Number: NCT05605899

Locations: 🇺🇸
UC San Diego Moores Cancer Center, La Jolla, California, United States
🇺🇸
Mayo Clinic, Phoenix, Arizona, United States
🇺🇸
University of California Los Angeles (UCLA), Los Angeles, California, United States

and more 84 locations

Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Diffuse Large B-cell Lymphoma

Phase 2

Recruiting

Conditions: High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements
Double-Expressor Lymphoma
High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements
High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements

Interventions: Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Etoposide
Biological: Loncastuximab Tesirine
Drug: Prednisone
Biological: Rituximab
Drug: Vincristine

First Posted Date: 2022-10-31

Last Posted Date: 2023-06-07

Lead Sponsor: Joseph Tuscano

Target Recruit Count: 24

Registration Number: NCT05600686

Locations: 🇺🇸
University of California Davis Comprehensive Cancer Center, Sacramento, California, United States

Intestinal Microbiota Impact for Prognosis and Treatment Outcomes in Early Luminal Breast Cancer and Pancreatic Cancer Patients

Recruiting

Conditions: Pancreas Cancer
Breast Cancer

Interventions: Drug: mFOLFIRINOX
Drug: Doxorubicin
Drug: Cyclophosphamid
Drug: Paclitaxel
Drug: Carboplatin

First Posted Date: 2022-10-14

Last Posted Date: 2022-10-14

Lead Sponsor: Moscow Clinical Scientific Center

Target Recruit Count: 35

Registration Number: NCT05580887

Locations: 🇷🇺
Moscow Clinical Scientific Center named after AS Loginov, Moscow, Not Required, Russian Federation

A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

Phase 3

Recruiting

Conditions: Diffuse Large B-Cell Lymphoma

Interventions: Drug: Epcoritamab
Drug: Cyclophosphamide
Drug: Rituximab
Drug: Vincristine
Drug: Doxorubicin
Drug: Prednisone

First Posted Date: 2022-10-13

Last Posted Date: 2024-12-04

Lead Sponsor: Genmab

Target Recruit Count: 900

Registration Number: NCT05578976

Locations: 🇺🇸
Orlando Health Cancer Institute /ID# 232626, Orlando, Florida, United States
🇺🇸
University of Illinois at Chicago /ID# 226889, Chicago, Illinois, United States
🇺🇸
University of Maryland, Baltimore /ID# 225421, Baltimore, Maryland, United States

and more 326 locations